Actinium Pharmaceuticals Inc. macht sich auf den Weg (Seite 16)
eröffnet am 10.06.15 18:13:59 von
neuester Beitrag 02.11.23 22:50:13 von
neuester Beitrag 02.11.23 22:50:13 von
Beiträge: 480
ID: 1.213.944
ID: 1.213.944
Aufrufe heute: 0
Gesamt: 68.989
Gesamt: 68.989
Aktive User: 0
ISIN: US00507W2061 · WKN: A2QA48 · Symbol: ATNM
8,1000
EUR
-1,40 %
-0,1150 EUR
Letzter Kurs 10.05.24 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,8800 | +57,45 | |
| 17,440 | +44,61 | |
| 1,9750 | +27,42 | |
| 1,8400 | +26,03 | |
| 4,9500 | +25,32 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,965 | -18,48 | |
| 0,7845 | -19,36 | |
| 3,3200 | -22,61 | |
| 0,6785 | -26,19 | |
| 3,3100 | -77,44 |
Beitrag zu dieser Diskussion schreiben
Feedback
Einschätzung bei sharewise:
.. stufen die API-Aktie als Buy ein.
Für die API Aktie gibt es aktuell 1 Buy und 1 Outperform Analystenmeinungen. Das durchschnittliche Kursziel für diese Aktie auf Basis der Analystenmeinungen liegt bei 8.97€.
Das bedeutet, dass der aktuelle Kurs um 451.83% steigen würde.
In der vergangenen Woche wurde die durchschnittliche Analystenmeinung zur API Aktie nicht verändert.
.. stufen die API-Aktie als Buy ein.
Für die API Aktie gibt es aktuell 1 Buy und 1 Outperform Analystenmeinungen. Das durchschnittliche Kursziel für diese Aktie auf Basis der Analystenmeinungen liegt bei 8.97€.
Das bedeutet, dass der aktuelle Kurs um 451.83% steigen würde.
In der vergangenen Woche wurde die durchschnittliche Analystenmeinung zur API Aktie nicht verändert.
Wie sehen andere Börsendienste ATNM:
Aktienbewertung / Schätzungen bei NSL:
Community Rating: 1y Target Est:
ATNM bewerten 67% optimistisch von 3 Bewertungen
Kursziel: $10
Aktienbewertung / Schätzungen bei NSL:
Community Rating: 1y Target Est:
ATNM bewerten 67% optimistisch von 3 Bewertungen
Kursziel: $10
Zitat aus Yahoo Finance Thread:
"
Biden outlines Cancer Moonshot efforts to break barriers (from CNN)
by nidadh • Jun 29, 2016 10:38 PM Flag
This all bodes well for ATNM
http://www.cnn.com/2016/06/29/health/biden-cancer-moonshot-c…
"He gave several examples of how difficult it is to collaborate in the cancer field and how hard it is for patients to navigate the current medical system to get better and more affordable life-saving care. Dozens of Moonshot initiatives aim to fix both problems.
One initiative is intended to expedite researchers' access to cancer compounds. Currently, it can take a scientist up to 18 months to negotiate with each individual company to get access to material. Under the Moonshot, the National Cancer Institute will work with 20 to 30 biotech and pharmaceutical companies to speed access to these compounds through one pre-approved list. This could hasten clinical trials and give cancer patients more drug options.
There will be a new strategic computing partnership between the Department of Energy and the National Cancer Institute and with the Department of Veterans Affairs to use some of the country's most advanced supercomputers to analyze data from preclinical cancer models to better understand how the disease works, to develop less toxic treatments and to figure out which treatment and prevention models work.
New cancer data will be available in the National Cancer Institute's Genomic Data Commons. The Food and Drug Administration is developing a program that will expedite the development of cancer drugs. And the Patent Office created a program that aims to halve the time it takes to review patent applications in select cancer therapy fields." Less
Sentiment: Strong Buy
"
"
Biden outlines Cancer Moonshot efforts to break barriers (from CNN)
by nidadh • Jun 29, 2016 10:38 PM Flag
This all bodes well for ATNM
http://www.cnn.com/2016/06/29/health/biden-cancer-moonshot-c…
"He gave several examples of how difficult it is to collaborate in the cancer field and how hard it is for patients to navigate the current medical system to get better and more affordable life-saving care. Dozens of Moonshot initiatives aim to fix both problems.
One initiative is intended to expedite researchers' access to cancer compounds. Currently, it can take a scientist up to 18 months to negotiate with each individual company to get access to material. Under the Moonshot, the National Cancer Institute will work with 20 to 30 biotech and pharmaceutical companies to speed access to these compounds through one pre-approved list. This could hasten clinical trials and give cancer patients more drug options.
There will be a new strategic computing partnership between the Department of Energy and the National Cancer Institute and with the Department of Veterans Affairs to use some of the country's most advanced supercomputers to analyze data from preclinical cancer models to better understand how the disease works, to develop less toxic treatments and to figure out which treatment and prevention models work.
New cancer data will be available in the National Cancer Institute's Genomic Data Commons. The Food and Drug Administration is developing a program that will expedite the development of cancer drugs. And the Patent Office created a program that aims to halve the time it takes to review patent applications in select cancer therapy fields." Less
Sentiment: Strong Buy
"
Kapitel - sorry
Hier wird gerade ein neues Kapital aufgeschlagen und wir sind von Anfang an dabei.
Trading Spotlight
Gestern in USA + 3% bei gutem Volumen - da dürfte heute mehr drin sein.
Actinium Pharmaceuticals Initiates Pivotal Phase 3 SIERRA Trial June 29, 2016
Endlich ! 
http://ir.actiniumpharma.com/press-releases/detail/176
Actinium Pharmaceuticals, Inc. Echtzeit-Börsenkurse
ATNM $1.75* +3.55%
*Realtime - Zum 6/28/2016 11:57:22 AM
ATNM $1.75* +3.55%
*Realtime - Zum 6/28/2016 11:57:22 AM
fast + 5% aktuell an der Amex
Hey, was geht ab ?Hat jemand was gelesen - gibt es News ?
Hat einer James Bond gesehen oder hat der wegen dem Brexit seinen Job verloren.
Durchsuchen
